Skip to main content

Table 1 Baseline characteristics of the study population

From: Prognostic value of platelet-to-lymphocyte ratios among critically ill patients with acute kidney injury

Characteristics

Platelet-to-lymphocyte ratio

P value

<90

90–311

≥312

Platelet-to-lymphocyte ratio

59.1

182.6

456.8

<0.001

Clinical parameters, n (%)

1708

6699

2454

 

Age, years

62.3 (15.9)

65.4 (15.9)

65.7 (15.5)

<0.001

Sex, n (%)

   

<0.001

 Male

992 (58.1)

3679 (54.9)

1260 (51.3)

 

 Female

716 (41.9)

3018 (45.1)

1194 (48.7)

 

Ethnicity, n (%)

   

<0.001

 White

1095 (64.10)

4636 (69.2)

1833 (74.7)

 

 Black

203 (11.9)

805 (12.0)

208 (8.5)

 

 Other

410 (24.0)

1256 (18.8)

413 (16.8)

 

SBP, mmHg

120.6 (26.4)

123.3 (26.3)

121.9 (26.0)

<0.001

DBP, mmHg

61.5 (18.6)

62.2 (18.1)

61.1 (17.3)

0.021

Heart rate, beats/minute

89.9 (20.9)

88.6 (19.9)

91.3 (20.0)

<0.001

Vasopressin use, n (%)

   

<0.001

 Yes

844 (49.4)

2728 (40.7)

1047 (42.7)

 

 No

864 (50.6)

3969 (59.3)

1407 (57.3)

 

Ventilator use, n (%)

   

<0.001

 Yes

1063 (62.2)

3528 (52.7)

1316 (53.6)

 

 No

645 (37.8)

3169 (47.3)

1138 (6.4)

 

Comorbidities

    

 Cardiac arrhythmias, n (%)

   

<0.001

  Yes

375 (22.0)

1944 (29.0)

696 (28.4)

 

  No

1333 (78.0)

4753 (71.0)

1758 (71.6)

 

 Valvular disease, n (%)

   

0.051

  Yes

177 (15.7)

740 (11.0)

228 (9.3)

 

  No

1531 (89.6)

5957 (89.0)

2226 (90.7)

 

 Pulmonary circulation, n (%)

  

0.599

  Yes

97 (5.7)

415 (6.2)

158 (6.4)

 

  No

1611 (94.3)

6282 (93.8)

2296 (93.6)

 

 Chronic pulmonary disease, n (%)

   

<0.001

  Yes

255 (14.9)

1343 (20.1)

558 (22.7)

 

  No

1453 (85.1)

5354 (79.9)

1896 (77.3)

 

 Liver disease, n (%)

   

<0.001

  Yes

300 (17.6)

492 (7.3)

108 (4.4)

 

  No

1408 (82.4)

6205 (92.7)

2346 (95.6)

 

 Lymphoma, n (%)

   

<0.001

  Yes

59 (3.5)

123 (1.8)

49 (2.0)

 

  No

1649 (96.5)

6574 (98.2)

2405 (98.0)

 

 Metastatic cancer, n (%)

   

<0.001

  Yes

62 (3.6)

280 (4.2)

203 (8.3)

 

  No

1646 (96.4)

6417 (95.8)

2251 (91.7)

 

 Solid tumor, n (%)

   

<0.001

  Yes

93 (5.4)

411 (6.1)

248 (10.1)

 

  No

1615 (94.6)

6286 (93.9)

2206 (89.9)

 

 Deficiency anemias, n (%)

   

0.046

  Yes

246 (14.4)

1014 (15.1)

416 (17.0)

 

  No

1462 (85.6)

5683 (84.9)

2038 (83.0)

 

Laboratory parameters

    

 PO2, mmHg

118.0 (74.0–279.0)

113.0 (75.0–237.0)

107.0 (72.3–201.0)

<0.001

 PCO2, mmHg

39.0 (34.0–46.0)

40.0 (34.0–47.0)

40.0 (34.0–47.0)

0.036

 Serum potassium, mmol/L

4.32 (0.89)

4.39 (0.91)

4.44 (0.95)

<0.001

 BUN, mg/dl

30.0 (20.0–47.0)

31.0 (21.0–49.0)

33.0 (21.0–52.0)

<0.001

 Serum bicarbonate, mmol/L

23.0 (19.0–26.0)

24.0 (20.0–27.0)

23.0 (20.0–27.0)

<0.001

 Serum pH

7.31 (0.14)

7.32 (0.12)

7.32 (0.12)

<0.001

 White blood cell count, 109/L

11.0 (7.4–16.5)

10.6 (7.6–15.1)

11.8 (8.1–16.5)

<0.001

 Neutrophil count, n (%)

65.9 (18.2)

77.6 (11.4)

83.5 (12.9)

<0.001

 Lymphocyte count, n (%)

19.0 (12.0–28.0)

12.0 (8.0–17.7)

5.9 (3.8– 8.8)

<0.001

 Platelet count, 109/L

122.0 (67.0–182.)

220.0 (164.0–287.0)

285.0 (206.0–383.8)

<0.001

Scoring systems

    

 GCS

14.0 (6.0–15.0)

15.0 (8.0–15.0)

15.0(9.0–15.0)

<0.001

 SOFA

7.0 (5.0–10.0)

5.0 (3.0– 8.0)

5.0 (3.0– 8.0)

<0.001

Renal function

    

 Serum creatinine, mg/dl

1.50 (1.10–2.40)

1.60 (1.20–2.40)

1.60 (1.20–2.50)

0.340

 Urine output, ml/24 h

1050 (372–2311)

1050 (395–2325)

900 (345–2095)

0.046

 eGFR, ml/min/1.73 m2

0.88 (0.76–0.94)

0.87 (0.77–0.95)

0.84 (0.76–0.94)

<0.001

 eGFR change

2.02 (1.17–4.27)

1.15 (1.86–3.76)

2.03 (1.25–4.16)

<0.001

 KDIGO stage, n (%)

   

0.084

  Stage 1

1081 (63.4)

4467(66.7)

1589 (64.8)

 

  Stage 2

407 (23.9)

1456 (21.8)

573 (23.3)

 

  Stage 3

218 (12.8)

776 (11.6)

292 (11.9)

 

 Renal replacement therapy

   

0.008

  Yes

71 (4.2)

189 (2.8)

66 (2.7)

 

  No

1635 (95.8)

6510 (97.2)

2388 (97.3)

 
  1. Abbreviations: BUN Blood urea nitrogen, DBP Diastolic blood pressure, eGFR, Estimated glomerular filtration rate; GCS Glasgow Coma Scale, KDIGO Kidney Disease: Improving Global Outcomes, PCO 2 Partial pressure of carbon dioxide, PO 2 Partial pressure of oxygen, SBP Systolic blood pressure, SOFA Sequential Organ Failure Assessment
  2. Normally distributed data are presented as the mean (SD) (analysis of variance); non-normally distributed data are presented as median (IQR) (nonparametric Wilcoxon test); and categorical variables are presented as n (%) (chi-square test)